Logo de TMX Newsfile
English

DIMERx INC.

DIMERx, Inc. is a clinical-stage biopharmaceutical company developing first-in-class, covalently linked dimer-based therapeutics to address major public-health challenges in pain management and the opioid crisis.

Nouvelles récentes

Jeffrey W. Sherman, MD, Joins DIMERx Board to Advance Next-Generation, Non-Addictive Pain Therapies

San Francisco, California--(Newsfile Corp. - March 3, 2026) - DIMERx, Inc. ("DIMERx" or "the Company"), is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis of drug abuse and dependence, with a portfolio of first-in-class, dimer-based pain therapeutics engineered to deliver effective analgesia without the addiction liabilities of conventional opioids. The Company announced the appointment of Jeffrey W. Sherman, MD, FACP, to its Board of Directors. Dr....

2026-03-03 9:00 AM EST

Prêt à annoncer en toute confiance?

Envoyez-nous un message, et un membre de notre équipe TMX Newsfile communiquera avec vous pour discuter de vos besoins.

Communiquez avec nous